Clinical experience with recently approved antibiotics

Current Opinion in Pharmacology

Volumn 6, Issue 5, 2006, Pages 486-490

  Paterson, David L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CALCINEURIN INHIBITOR; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; LINEZOLID; METICILLIN; NARCOTIC ANALGESIC AGENT; PENICILLIN DERIVATIVE; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; LACTIC ACIDOSIS; MYALGIA; NAUSEA; NONHUMAN; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; VEIN DISEASE; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DAPTOMYCIN; HUMANS; MINOCYCLINE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; VIRGINIAMYCIN;

EID: 33748476097     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.07.001     Document Type: Review

References (44)

1. Eliopoulos G.M. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 36 (2003) 473-481
2. Linden P.K., Moellering Jr. R.C., Wood C.A., Rehm S.J., Flaherty J., Bompart F., and Talbot G.H. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 33 (2001) 1816-1823
3. Moellering R.C., Linden P.K., Reinhardt J., Blumberg E.A., Bompart F., and Talbot G.H. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 44 (1999) 251-261
4. Hershberger E., Donabedian S., Konstantinou K., and Zervos M.J. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 38 (2004) 92-98
5. Oh W.S., Ko K.S., Song J.H., Lee M.Y., Park S., Peck K.R., Lee N.Y., Kim C.K., Lee H., Kim S.W., et al. High rate of resistance to quinupristin-dalfopristin in Enterococcus faecium clinical isolates from Korea. Antimicrob Agents Chemother 49 (2005) 5176-5178
6. Paterson D.L., and Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 25 (1997) 1430-1440
7. Raad I., Hachem R., Hanna H., Afif C., Escalante C., Kantarjian H., and Rolston K. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 53 (2004) 646-649
8. Falagas M.E., Manta K.G., Ntziora F., and Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58 (2006) 273-280. This is an important review of cases and case-series of patients with endocarditis who were treated with linezolid.
9. Paterson D.L., Dominguez E.A., Chang F.Y., Snydman D.R., and Singh N. Infective endocarditis in solid organ transplant recipients. Clin Infect Dis 26 (1998) 689-694
10. Steinmetz M.P., Vogelbaum M.A., De Georgia M.A., Andrefsky J.C., and Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 29 (2001) 2383-2385
11. Tsai T.N., Wu C.P., Peng M.Y., Giian C.F., Lee S.Y., and Lu J.J. Short course of linezolid treatment for vancomycin-resistant Enterococcus faecium meningitis. Int J Clin Pract 60 (2006) 740-741
12. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
13. Herrero I.A., Issa N.C., and Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 346 (2002) 867-869
14. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
15. Rayner C.R., Baddour L.M., Birmingham M.C., Norden C., Meagher A.K., and Schentag J.J. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 32 (2004) 8-14
16. Lipsky B.A., Itani K., and Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 38 (2004) 17-24
17. Wu V.C., Wang Y.T., Wang C.Y., Tsai I.J., Wu K.D., Hwang J.J., and Hsueh P.R. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 42 (2006) 66-72. An important description of this common clinical problem.
18. Bishop E., Melvani S., Howden B.P., Charles P.G., and Grayson M.L. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50 (2006) 1599-1602. The authors propose a practical algorithm for preventing toxicity from linezolid.
19. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
20. Powers J.H., Ross D.B., Lin D., and Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 126 (2004) 314-315 author reply 315-316
21. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
22. Potoski B.A., Adams J., Clarke L., Shutt K., Linden P.K., Baxter C., Pasculle A.W., Capitano B., Peleg A.Y., Szabo D., et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 43 (2006) 165-171. This article is the first to describe the epidemiology of linezolid resistance in staphylococci. Although the organism was coagulase-negative staphylococcus in this instance, an analogous situation could arise with MRSA.
23. Palenzuela L., Hahn N.M., Nelson Jr. R.P., Arno J.N., Schobert C., Bethel R., Ostrowski L.A., Sharma M.R., Datta P.P., Agrawal R.K., et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?. Clin Infect Dis 40 (2005) e113-e116
24. Kopterides P., Papadomichelakis E., and Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis 37 (2005) 153-154
25. Spellberg B., Yoo T., and Bayer A.S. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 54 (2004) 832-835
26. Bressler A.M., Zimmer S.M., Gilmore J.L., and Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4 (2004) 528-531
27. Frippiat F., Bergiers C., Michel C., Dujardin J.P., and Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 53 (2004) 1114-1115
28. Silverman J.A., Mortin L.I., Vanpraagh A.D., Li T., and Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152. This article explains the surprising lack of efficacy of daptomycin in the treatment of pneumonia.
29. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
30. Lipsky B.A., and Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55 (2005) 240-245
31. Cunha B.A., Hamid N., Kessler H., and Parchuri S. Daptomycin cure after cefazolin treatment failure of Methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung 34 (2005) 442-447
32. Cunha B.A., Eisenstein L.E., and Hamid N.S. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 35 (2006) 207-211
33. Segreti J.A., Crank C.W., and Finney M.S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26 (2006) 347-352
34. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44 (2006) 655-656
35. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering Jr. R.C., and Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 (2006) 1581-1585
36. Hirschwerk D., Ginocchio C.C., Bythrow M., and Condon S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 27 (2006) 315-317
37. Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., Gold H.S., Baden L.R., and Pillai S.K. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44 (2006) 595-597. This article describes the emergence of daptomycin resistance during therapy.
38. Bauer G., Berens C., Projan S.J., and Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 53 (2004) 592-599
39. Bradford P.A., Weaver-Sands D.T., and Petersen P.J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41 Suppl 5 (2005) S315-S332
40. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5 (2005) S341-S353
41. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., and Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl 5 (2005) S354-S367
42. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 41 Suppl 5 (2005) S333-S340
43. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 43 (2006) 518-524. This is an excellent review of the pharmacokinetic and pharmacodynamic properties of tigecycline.
44. Taccone F.S., Rodriguez-Villalobos H., De Backer D., De Moor V., Deviere J., Vincent J.L., and Jacobs F. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25 (2006) 257-260